May 15, 2017
Alpha Cancer Technologies Inc. Announces Presentation of ACT-101 Study Results in Pre-Clinical Model of Myasthenia Gravis (MG) at the 13th International Conference on Myasthenia Gravis and Related Disorders
Alpha Cancer Technologies Inc. (ACT) a biopharmaceutical company focused on developing and commercializing innovative therapies for patients with autoimmune diseases and cancer based on its proprietary recombinant human Alpha Fetoprotein today announced that an abstract highlighting the results of a study of ACT-101 (recombinant human alpha fetoprotein or AFP) in the treatment of myasthenia gravis has been presented at the 13th International Conference on Myasthenia Gravis and Related Disorders held on May 15-17, 2017 in New York. This conference was organized by the Myasthenia Gravis Foundation of America and the New York Academy of Sciences. The study was presented by the principal investigator, by Dr. Linda Kusner of the Laboratory for Myasthenia Gravis Research at George Washington University School of Medicine & Health Sciences.
December 20, 2015
Emerging Health Technologies Can Enhance Canada’s Prosperity
Canadian pharmaceutical company Alpha Cancer Technologies Inc. is developing a way to deliver chemotherapy more effectively and with lower doses so the treatment does not cause toxicity in patients.
May 28, 2014
PolyTherics and Alpha Cancer Technologies Collaborate to Produce Novel Drug Conjugates to Target Tumours
PolyTherics Limited (“PolyTherics”), an Abzena company that provides technologies and services to enable the development of better biopharmaceuticals, today announced a collaboration with Alpha Cancer Technologies Inc. (“ACT”), a Canadian company with a targeted drug delivery platform based on alpha fetoprotein (“AFP”). PolyTherics will produce a range of AFP drug conjugates for ACT to test using its proprietary ThioBridge™ technology.
March 11, 2014
Alpha Cancer To Test Oncology Game Changer
AFP is a carrier protein known for transporting nutrients to rapidly growing fetal cells. Only trace amounts of the protein are found following birth, but importantly, receptors for AFP show up again on cancer cells to help shuttle nutrients to rapidly growing cancer cells.
January 15, 2014
Strength From Within
Despite seemingly daily reports of the newest wonder drug that shrinks tumours, gene therapies or even a vaccine there really hasn’t been much progress treating the disease over the last half-century. In 1960, the mortality rate for all cancers combined in the United States was 194 deaths per 100,000 people. In 2009, the mortality rate was 174 deaths for every 100,000 persons.